 | |
| Clinical data | |
|---|---|
| Other names | SH-368; Estradiol undecenoate; Estra-1,3,5(10)-triene-3,17β-diol 17β-(10-undecenoate) |
|
Routes of administration | Intramuscular injection |
| Drug class | Estrogen; Estrogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.080.203 |
| Chemical and physical data | |
| Formula | C29H42O3 |
| Molar mass | 438.652 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Estradiol undecylenate (EUe; developmental code name SH-368) [1] is an estrogen medication and estrogen ester which was never marketed. [2] It is the C17β undecenoate (undecylenate) ester of estradiol. [2] Following an intramuscular injection, EUe has a very prolonged effect, exceeding that of other estradiol esters like estradiol valerate and estradiol enanthate. [3] Due to its very long duration of action, EUe releases only subthreshold amounts of estradiol at conventional doses. [3] However, this may still be useful in menopausal hormone therapy. [3]
See also
References
-
^
Unlisted Drugs. Pharmaceutical Section, Special Libraries Association. 1975.
ISBN
978-0-913210-02-4.
estradiol undecylate [...] Delestrec [...] SQ 9993 [...] estradiol undecylenate [...] SH 368
- ^ a b DE 1096904, Ringold HJ, Batres E, Rosenkranz G, "Estradiol 17-undecenoate", published 12 January 1961, assigned to Svntex S.A.
- ^
a
b
c Harper NJ (1962).
"Drug Latentiation". In Jucker E (ed.). Fortschritte der Arzneimittelforschung / Progress in Drug Research / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 243–.
ISBN
978-3-0348-7044-3.
Retarded estrogens. In animal experiments it has been shown esterification at C-17 results in longer retarding effects than esterification at C-3. The optimal retarding effect (exceeding 29 days) may be obtained with the C-17 oenanthate. However, the effect exceeds the time interval of 28 days normally considered sufficient for the treatment of a female during one period and for this reason the shorter active estradiol-17-valerianate has been introduced. The estradiol undecylenate has a more protracted effect but it releases only subthreshold doses of steroid (advantage may be taken of this for the treatment of menopause).
 | This article about a steroid is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
| Other names | SH-368; Estradiol undecenoate; Estra-1,3,5(10)-triene-3,17β-diol 17β-(10-undecenoate) |
|
Routes of administration | Intramuscular injection |
| Drug class | Estrogen; Estrogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.080.203 |
| Chemical and physical data | |
| Formula | C29H42O3 |
| Molar mass | 438.652 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Estradiol undecylenate (EUe; developmental code name SH-368) [1] is an estrogen medication and estrogen ester which was never marketed. [2] It is the C17β undecenoate (undecylenate) ester of estradiol. [2] Following an intramuscular injection, EUe has a very prolonged effect, exceeding that of other estradiol esters like estradiol valerate and estradiol enanthate. [3] Due to its very long duration of action, EUe releases only subthreshold amounts of estradiol at conventional doses. [3] However, this may still be useful in menopausal hormone therapy. [3]
See also
References
-
^
Unlisted Drugs. Pharmaceutical Section, Special Libraries Association. 1975.
ISBN
978-0-913210-02-4.
estradiol undecylate [...] Delestrec [...] SQ 9993 [...] estradiol undecylenate [...] SH 368
- ^ a b DE 1096904, Ringold HJ, Batres E, Rosenkranz G, "Estradiol 17-undecenoate", published 12 January 1961, assigned to Svntex S.A.
- ^
a
b
c Harper NJ (1962).
"Drug Latentiation". In Jucker E (ed.). Fortschritte der Arzneimittelforschung / Progress in Drug Research / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 243–.
ISBN
978-3-0348-7044-3.
Retarded estrogens. In animal experiments it has been shown esterification at C-17 results in longer retarding effects than esterification at C-3. The optimal retarding effect (exceeding 29 days) may be obtained with the C-17 oenanthate. However, the effect exceeds the time interval of 28 days normally considered sufficient for the treatment of a female during one period and for this reason the shorter active estradiol-17-valerianate has been introduced. The estradiol undecylenate has a more protracted effect but it releases only subthreshold doses of steroid (advantage may be taken of this for the treatment of menopause).
|
| This article about a steroid is a stub. You can help Wikipedia by expanding it. |
|
| This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |